{"id":500197,"date":"2021-06-02T16:11:34","date_gmt":"2021-06-02T20:11:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/"},"modified":"2021-06-02T16:11:34","modified_gmt":"2021-06-02T20:11:34","slug":"alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/","title":{"rendered":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting<\/b><\/p>\n<p>SEATTLE&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today made an oral presentation of preclinical data from the company\u2019s ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting, entitled \u201cALPN-303, an Enhanced, Potent Dual BAFF\/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases.\u201d\n<\/p>\n<p>\nPresentation highlights include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody.\n<\/li>\n<li>\nALPN-303 exhibited superior preclinical pharmacokinetics and pharmacodynamics than wild-type TACI-Fc counterparts, including superior serum exposure, suppression of T-dependent antibody production, and\/or serum immunoglobulins in mice and\/or cynomolgus monkeys.\n<\/li>\n<li>\nIn a mouse model of lupus, ALPN-303 treatment significantly suppressed anti-double stranded DNA antibody titers, inflammation in the kidneys (glomerulonephritis) and salivary glands (sialadenitis), while preserving renal function and improving survival.\n<\/li>\n<\/ul>\n<p>\n\u201cWe\u2019re particularly excited by these findings,\u201d commented Dr. Stanford Peng, Alpine\u2019s President and Head of Research and Development. \u201cThere continues to be significant interest in novel therapeutics that target the APRIL and BAFF pathways, and these data suggest that ALPN-303 may be superior for the treatment of severe diseases like lupus. We hope to initiate its first-in-human study later this year.\u201d\n<\/p>\n<p>\nThis oral presentation is live on the EULAR congress website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcongress.eular.org%2F&amp;esheet=52438967&amp;newsitemid=20210602005925&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcongress.eular.org%2F&amp;index=1&amp;md5=a793fb7254411e56791b5037e3a08bd8\">https:\/\/congress.eular.org\/<\/a> A copy of the oral presentation slides are available on the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alpineimmunesciences.com%2Fscientific-publications%2F&amp;esheet=52438967&amp;newsitemid=20210602005925&amp;lan=en-US&amp;anchor=Scientific+Publications+page&amp;index=2&amp;md5=3652c2d235281b2e457d744adf2aa12a\">Scientific Publications page<\/a> of Alpine\u2019s website.\n<\/p>\n<p><b>About ALPN-303<\/b><\/p>\n<p>\nALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and\/or inflammatory diseases. Engineered by directed evolution, ALPN-303 potently inhibits the pleiotropic B cell cytokines B cell activating factor (BAFF, BLyS) and a proliferation inducing ligand (APRIL), which play key roles in B cell development, differentiation, and survival, and together contribute to the pathogenesis of multiple autoimmune diseases like systemic lupus erythematosus (SLE), Sj\u00f6gren\u2019s syndrome, inflammatory arthritis, multiple sclerosis, and many others. By simultaneously blocking these two cytokines, ALPN-303 has the potential to improve outcomes in patients suffering from severe autoimmune and\/or inflammatory diseases.\n<\/p>\n<p><b>About Alpine Immune Sciences, Inc. <\/b><\/p>\n<p>\nAlpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients\u2019 lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alpineimmunesciences.com&amp;esheet=52438967&amp;newsitemid=20210602005925&amp;lan=en-US&amp;anchor=www.alpineimmunesciences.com&amp;index=3&amp;md5=c367d1141fee6eb37540e81bc7a9df1b\">www.alpineimmunesciences.com<\/a>. Follow <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAlpineImmuneSci&amp;esheet=52438967&amp;newsitemid=20210602005925&amp;lan=en-US&amp;anchor=%40AlpineImmuneSci&amp;index=4&amp;md5=c44db6754b3ee4583d893b76230a194c\">@AlpineImmuneSci<\/a> on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAlpineImmuneSci&amp;esheet=52438967&amp;newsitemid=20210602005925&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=7ef33fcb5f3008563289663f0ab099da\">Twitter<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Falpine-immune-sciences%2F&amp;esheet=52438967&amp;newsitemid=20210602005925&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=79ec5c479a018d7fd0ef0c2cb6c9f6e0\">LinkedIn<\/a>.\n<\/p>\n<p>\n\u201cSecreted Immunomodulatory Proteins\u201d, \u201cSIP\u201d, \u201cTransmembrane Immunomodulatory Protein,\u201d \u201cTIP,\u201d \u201cVariant Ig Domain,\u201d \u201cvIgD\u201d and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.\n<\/p>\n<p>\nSource: Alpine Immune Sciences Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210602005925\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210602005925\/en\/<\/a><\/span><\/p>\n<p>\nAlex Sharif<br \/>\n<br \/>Director, Investor Relations and Corporate Development<br \/>\n<br \/>Alpine Immune Sciences, Inc.<br \/>\n<br \/>206-788-4545<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@alpineimmunesciences.com\">ir@alpineimmunesciences.com<br \/>\n<\/a><\/p>\n<p>Laurence Watts<br \/>\n<br \/>Managing Director<br \/>\n<br \/>Gilmartin Group, LLC.<br \/>\n<br \/>619-916-7620<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:laurence@gilmartinir.com\">laurence@gilmartinir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Washington<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting SEATTLE&#8211;(BUSINESS WIRE)&#8211; Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today made an oral presentation of preclinical data from the company\u2019s ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting, entitled \u201cALPN-303, an Enhanced, Potent Dual BAFF\/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases.\u201d Presentation highlights include: ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody. ALPN-303 exhibited superior preclinical pharmacokinetics &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-500197","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting SEATTLE&#8211;(BUSINESS WIRE)&#8211; Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today made an oral presentation of preclinical data from the company\u2019s ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting, entitled \u201cALPN-303, an Enhanced, Potent Dual BAFF\/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases.\u201d Presentation highlights include: ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody. ALPN-303 exhibited superior preclinical pharmacokinetics &hellip; Continue reading &quot;Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-02T20:11:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting\",\"datePublished\":\"2021-06-02T20:11:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/\"},\"wordCount\":569,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/\",\"name\":\"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-06-02T20:11:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting - Market Newsdesk","og_description":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting SEATTLE&#8211;(BUSINESS WIRE)&#8211; Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today made an oral presentation of preclinical data from the company\u2019s ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting, entitled \u201cALPN-303, an Enhanced, Potent Dual BAFF\/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases.\u201d Presentation highlights include: ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody. ALPN-303 exhibited superior preclinical pharmacokinetics &hellip; Continue reading \"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-02T20:11:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting","datePublished":"2021-06-02T20:11:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/"},"wordCount":569,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/","name":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-06-02T20:11:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210602005925r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/500197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=500197"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/500197\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=500197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=500197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=500197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}